{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:14:31Z","timestamp":1793304871570,"version":"4.5.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,10]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Cell-free DNA and circulating tumor cells are related to TMTV in follicular lymphoma at diagnosis. Cell-free DNA levels, in addition to TMTV, define high-risk follicular lymphoma patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017015164","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T12:00:14Z","timestamp":1523361614000},"page":"807-816","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":131,"title":["Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-2343","authenticated-orcid":false,"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"first","affiliation":[{"name":"Hematologic and Immunologic Biology Department, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"},{"name":"INSERM U955 Team 9, Cr\u00e9teil, France;"},{"name":"Paris-Est Cr\u00e9teil University, Cr\u00e9teil, France;"},{"name":"Lymphoma Study Association, Pierre-Benite, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"van der Gucht","sequence":"additional","affiliation":[{"name":"Paris-Est Cr\u00e9teil University, Cr\u00e9teil, France;"},{"name":"Nuclear Medicine Department and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan","family":"Dupuis","sequence":"additional","affiliation":[{"name":"Lymphoma Study Association, Pierre-Benite, France;"},{"name":"Lymphoid Hemopathy Unit, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Jais","sequence":"additional","affiliation":[{"name":"Lymphoma Study Association, Pierre-Benite, France;"},{"name":"Biostatistics Department, Assistance Publique H\u00f4pitaux de Paris, Necker, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Nel","sequence":"additional","affiliation":[{"name":"Hematologic and Immunologic Biology Department, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Beldi-Ferchiou","sequence":"additional","affiliation":[{"name":"Hematologic and Immunologic Biology Department, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"},{"name":"Paris-Est Cr\u00e9teil University, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Hamdane","sequence":"additional","affiliation":[{"name":"Hematologic and Immunologic Biology Department, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichrafe","family":"Benmaad","sequence":"additional","affiliation":[{"name":"Hematologic and Immunologic Biology Department, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Laboure","sequence":"additional","affiliation":[{"name":"Lymphoid Hemopathy Unit, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Verret","sequence":"additional","affiliation":[{"name":"Lymphoid Hemopathy Unit, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[{"name":"INSERM U955 Team 9, Cr\u00e9teil, France;"},{"name":"Paris-Est Cr\u00e9teil University, Cr\u00e9teil, France;"},{"name":"Lymphoma Study Association, Pierre-Benite, France;"},{"name":"Lymphoid Hemopathy Unit, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Copie-Bergman","sequence":"additional","affiliation":[{"name":"INSERM U955 Team 9, Cr\u00e9teil, France;"},{"name":"Paris-Est Cr\u00e9teil University, Cr\u00e9teil, France;"},{"name":"Lymphoma Study Association, Pierre-Benite, France;"},{"name":"Pathology Department, Assistance Publique H\u00f4pitaux de Paris, HU Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Berriolo-Riedinger","sequence":"additional","affiliation":[{"name":"Lymphoma Study Association, Pierre-Benite, France;"},{"name":"Nuclear Medicine Department, Centre GF Leclerc, Dijon, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippine","family":"Robert","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, CHU Le Bocage and INSERM UMR1231, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"Lymphoma Study Association, Pierre-Benite, France;"},{"name":"Department of Clinical Hematology, CHU Le Bocage and INSERM UMR1231, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[{"name":"Paris-Est Cr\u00e9teil University, Cr\u00e9teil, France;"},{"name":"Lymphoma Study Association, Pierre-Benite, France;"},{"name":"Nuclear Medicine Department and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"2019111618085425600_B1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"7","key":"2019111618085425600_B2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"2019111618085425600_B3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111618085425600_B4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2019111618085425600_B5","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111618085425600_B6","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111618085425600_B7","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111618085425600_B8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"2019111618085425600_B9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hon.2214","article-title":"VI. FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis","volume":"33","author":"Meignan","year":"2015","journal-title":"Hematol Oncol"},{"issue":"6","key":"2019111618085425600_B10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2019111618085425600_B11","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies [published online ahead of print 22 August 2016]","author":"Meignan","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111618085425600_B12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjh.12675","article-title":"Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis","volume":"164","author":"Sarkozy","year":"2014","journal-title":"Br J Haematol"},{"issue":"20","key":"2019111618085425600_B13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198211113072002","article-title":"Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin\u2019s lymphoma","volume":"307","author":"Yunis","year":"1982","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111618085425600_B14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.leu.2404479","article-title":"Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936","volume":"21","author":"Evans","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"2019111618085425600_B15","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2004-06-2490","article-title":"Quantitative PCR of bone marrow BCL2\/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma","volume":"105","author":"Rambaldi","year":"2005","journal-title":"Blood"},{"issue":"24","key":"2019111618085425600_B16","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111618085425600_B17","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","article-title":"Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy","volume":"126","author":"Zohren","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111618085425600_B18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111618085425600_B19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.12439","article-title":"Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma","volume":"163","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111618085425600_B20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111618085425600_B21","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.3324\/haematol.2015.123612","article-title":"Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis","volume":"100","author":"Bohers","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"2019111618085425600_B22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2016.1139703","article-title":"Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma","volume":"57","author":"Camus","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"364","key":"2019111618085425600_B23","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"24","key":"2019111618085425600_B24","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2019111618085425600_B25","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111618085425600_B26","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"2019111618085425600_B27","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","article-title":"Cell-free circulating DNA in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas","volume":"20","author":"Hohaus","year":"2009","journal-title":"Ann Oncol"},{"issue":"18","key":"2019111618085425600_B28","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111618085425600_B29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111618085425600_B30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"22","key":"2019111618085425600_B31","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"issue":"6","key":"2019111618085425600_B32","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J Mol Diagn"},{"issue":"12","key":"2019111618085425600_B33","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"issue":"11","key":"2019111618085425600_B34","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2019111618085425600_B35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"2019111618085425600_B36","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"9759","key":"2019111618085425600_B37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"2019111618085425600_B38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2012.172","article-title":"Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma","volume":"27","author":"Tilly","year":"2013","journal-title":"Leukemia"},{"issue":"35","key":"2019111618085425600_B39","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111618085425600_B40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdw026","article-title":"Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol"},{"issue":"17","key":"2019111618085425600_B41","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood-2014-02-553693","article-title":"Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma","volume":"123","author":"Sarkozy","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111618085425600_B42","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin\u2019s lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"issue":"6","key":"2019111618085425600_B43","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/annonc\/mds657","article-title":"Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation","volume":"24","author":"Metzner","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111618085425600_B44","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","article-title":"Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi","volume":"101","author":"Luminari","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"2019111618085425600_B45","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"issue":"4","key":"2019111618085425600_B46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00259-014-2973-6","article-title":"FDG PET\/CT imaging as a biomarker in lymphoma","volume":"42","author":"Meignan","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"2019111618085425600_B47","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111618085425600_B48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol"},{"key":"2019111618085425600_B49","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.humpath.2017.03.023","article-title":"Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients","volume":"64","author":"Xerri","year":"2017","journal-title":"Hum Pathol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/7\/807\/880675\/advances015164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/7\/807\/880675\/advances015164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T18:09:09Z","timestamp":1573927749000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/7\/807\/15817\/Total-metabolic-tumor-volume-circulating-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,4,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017015164","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]}}}